Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

A Multicentre, Single Arm Study Evaluating The Extension From Weekly To Once Every Other Week Darbepoetin Alfa Administration In Subjects With Chronic Kidney Disease Receiving Dialysis.

The purpose of this study is to assess the proportion of subjects sucessfully achieving a mean Hemoglobin greater than or equal to 11 g/dL during the evaluation period following extension from Weekly (QW) to Once Every Other Week (Q2W) Darbepoetin Alfa administraion.

Inclusion Criteria:

• Receiving dialysis for 3 months or more before enrollment.
• The mean of 2 screening Hb values taken at least 7 days appart must be greater than or equal to 11g/dL and less than or equal to 13.0 g/dL
• Receiving stable QW darbepoetin alfa doses for at least 6 weeks before enrollment
• Adequate iron stores (serum ferritin equal to or greater than 100 ug/L

Exclusion Criteria:

• Uncontrolled hypertension
• Prior history of Cardiovascular Incidents 12 weeks prior to enrollment
• Other hematological disorders
• Upper or lower GI bleed within the prior 6 months